Los Angeles Capital Management’s Bioventus BVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$639 Sell
70
-67,898
-100% -$569K ﹤0.01% 2356
2025
Q4
$460K Sell
67,968
-2,938
-4% -$21.1K ﹤0.01% 922
2025
Q3
$474K Sell
70,906
-50,929
-42% -$353K ﹤0.01% 957
2025
Q2
$807K Buy
121,835
+22,915
+23% +$162K ﹤0.01% 708
2025
Q1
$905K Sell
98,920
-1,400
-1% -$14K ﹤0.01% 596
2024
Q4
$1.05M Sell
100,320
-43,144
-30% -$510K ﹤0.01% 604
2024
Q3
$1.71M Buy
+143,464
New +$1.24M 0.01% 495
2022
Q2
Sell
-20,774
Closed -$293K 1338
2022
Q1
$293K Buy
20,774
+6,980
+51% +$93.4K ﹤0.01% 1249
2021
Q4
$200K Buy
+13,794
New +$196K ﹤0.01% 1350

Other funds holding BVS

Los Angeles Capital Management's BVS Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Bioventus (BVS) stake by 100% in Q1 2026, selling an estimated $569K and leaving 70 shares worth $639. The position accounts for ﹤0.01% of the portfolio, ranked #2356.

Los Angeles Capital Management first reported a position in BVS in Q4 2021 and has held it in 9 quarters since. The position peaked at $1.71M in Q3 2024. 157 funds tracked by Wall St. Rank hold BVS as of Q1 2026.

  • Los Angeles Capital Management held 70 shares of Bioventus worth $639 as of Q1 2026.
  • Los Angeles Capital Management sold 67,898 Bioventus shares in Q1 2026, an estimated $569K.
  • Bioventus made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #2356 holding.
  • Los Angeles Capital Management first reported a position in Bioventus in Q4 2021 and has held it in 9 quarters since.
  • Los Angeles Capital Management's Bioventus position peaked at $1.71M in Q3 2024.
  • 157 funds tracked by Wall St. Rank held Bioventus as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.